Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-27.87 Insider Own94.74% Shs Outstand1.79M Perf Week-0.23%
Market Cap269.91M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.67M Perf Month8.54%
Income-75.48M PEG- EPS next Q- Inst Own2.53% Short Float1.10% Perf Quarter19.66%
Sales0.37M P/S729.50 EPS this Y- Inst Trans-73.39% Short Ratio1.69 Perf Half Y30.81%
Book/sh2.57 P/B3.31 EPS next Y- ROA-50.10% Short Interest0.02M Perf Year-2.54%
Cash/sh2.78 P/C3.07 EPS next 5Y47.30% ROE-64.53% 52W Range4.35 - 9.36 Perf YTD14.36%
Dividend Est.- P/FCF- EPS past 5Y-80.47% ROI-76.41% 52W High-8.97% Beta1.75
Dividend TTM- Quick Ratio10.60 Sales past 5Y35.36% Gross Margin-2944.84% 52W Low95.86% ATR (14)0.51
Dividend Ex-Date- Current Ratio10.60 EPS Y/Y TTM25.42% Oper. Margin-21387.77% RSI (14)58.98 Volatility3.74% 6.36%
Employees102 Debt/Eq0.25 Sales Y/Y TTM-89.62% Profit Margin-20509.78% Recom5.00 Target Price5.00
Option/ShortNo / Yes LT Debt/Eq0.21 EPS Q/Q41.15% Payout- Rel Volume0.14 Prev Close8.81
Sales Surprise33.33% EPS Surprise-16.89% Sales Q/Q-89.59% EarningsNov 14 BMO Avg Volume10.83K Price8.52
SMA207.20% SMA506.82% SMA20021.32% Trades Volume1,537 Change-3.29%
Date Action Analyst Rating Change Price Target Change
Jan-07-22Downgrade BofA Securities Neutral → Underperform $3
Sep-27-21Downgrade JP Morgan Neutral → Underweight $10 → $7
Aug-31-21Downgrade BTIG Research Buy → Neutral
Aug-12-21Downgrade Piper Sandler Overweight → Neutral $13 → $9
Aug-11-21Downgrade JP Morgan Overweight → Neutral $17 → $10
Mar-09-21Initiated Piper Sandler Overweight $17
Mar-09-21Initiated JP Morgan Overweight $18
Mar-09-21Initiated BTIG Research Buy $18
Mar-09-21Initiated BofA Securities Neutral $14
Nov-14-23 08:27AM
Aug-10-23 04:45PM
Aug-03-23 08:00AM
08:00AM Loading…
Aug-02-23 08:00AM
Jul-27-23 08:00AM
Jul-24-23 08:00AM
Jul-05-23 08:00AM
May-23-23 08:00AM
May-11-23 05:22PM
May-04-23 08:00AM
Mar-22-23 04:05PM
Nov-09-22 06:13AM
04:05PM Loading…
Nov-03-22 04:05PM
Aug-08-22 10:48AM
Aug-03-22 07:50AM
Aug-02-22 04:05PM
May-10-22 04:05PM
Apr-26-22 08:00AM
Apr-25-22 12:08PM
Apr-06-22 06:11PM
Mar-15-22 09:30PM
Mar-01-22 08:00AM
Feb-23-22 04:23AM
Feb-01-22 10:05AM
Dec-25-21 02:38AM
02:00PM Loading…
Dec-21-21 02:00PM
Dec-20-21 04:00PM
Dec-14-21 11:16AM
Dec-13-21 11:30PM
Dec-10-21 09:00AM
Dec-09-21 06:16PM
Dec-08-21 07:30PM
Dec-03-21 03:15PM
Dec-02-21 06:53PM
Nov-16-21 06:00AM
Nov-15-21 04:05PM
Nov-12-21 12:00PM
Nov-11-21 04:00PM
Nov-08-21 08:00AM
Oct-26-21 08:00AM
Oct-12-21 12:36PM
Sep-14-21 04:00PM
Sep-13-21 07:00PM
Sep-09-21 06:00PM
Sep-03-21 08:49AM
Aug-31-21 08:25PM
Aug-30-21 04:30PM
Aug-11-21 02:10PM
Aug-10-21 04:05PM
Jul-27-21 08:00AM
May-12-21 08:00AM
May-11-21 04:05PM
May-04-21 08:00AM
Apr-28-21 08:00AM
Mar-18-21 08:00AM
Mar-09-21 10:07AM
Mar-08-21 08:00AM
Feb-17-21 04:05PM
Feb-12-21 05:05PM
Feb-11-21 11:39PM
Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Redwood City, CA.